Age and sex in drug development and testing for adults
Cara Tannenbaum1, Danielle Day2,
1Institute of Gender and Health, Canadian Institutes of Health Research, Canada; Medicine and Pharmacy, Université de Montreal, Centre de recherche, Institut universitaire de gériatrie de Montréal (CRIUGM), 4565 Chemin Queen-Mary, Montréal, Québec H3W 1W5, Canada.
Abstract:
Individualization of drug therapy requires that the right drug be administered at the correct dose to patients who are likely to achieve the highest benefit and lowest risk. Female sex and age comprise two important risk factors for altered drug exposure and response. This review summarizes the current state of science for considering age and sex-related factors along the drug development pipeline, from cell culture and animal research through all phases of clinical trials in humans. A set of recommendations is provided to improve standards for integrating age and sex into the study design, analysis, and reporting of pre-clinical and clinical assessment of new molecular entities and biologics in adults.
Related Concept Videos
Pharmacodynamics in Geriatric Patients: Effects of Age
Drug Dosing: Geriatric Patients
Drug Toxicity: Risk factors
Factors Affecting Drug Response: Overview
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution


